focus -WSS

focus

author：comprehensive 2025-09-03 05:28:46 - browse：874

Adobe

The Food and Drug Administration is expected to approve Merck’s drug to treat a rare lung disorder called pulmonary arterial hypertension on Tuesday, making available a novel treatment for a deadly condition that’s long been challenging to treat.

In a large trial published last year, the drug, called sotatercept, exceeded expectations in significantly increasing the distance that patients could walk and cutting the risk that their condition would worsen, that they would die, and that they would need new treatments.

Pulmonary arterial hypertension, or PAH, is estimated to occur in 15 to 50 per million people, mostly in women. It’s characterized by a proliferation of cells in the blood vessels that connect the right side of heart to the lungs, making it harder for blood to pass through and leading the heart to have to work harder to pump blood into the lungs. The disease, which causes difficulty breathing, fatigue and dizziness, has a high mortality rate, with one study finding that one-fifth of patients died at around three years after diagnosis.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： UnitedHealth’s board chair also owns a personal investment firm

leisure time

WSS

Why police arrested suspected Gilgo Beach killer away from his house

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Care demand spikes challenge UnitedHealth’s provider arm

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Does aspartame cause cancer? What new WHO guidance says

Everything to know for the next Powerball drawing as jackpot hits $1 billion

hotspot

focus

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

Studies point to risks of excluding people with obesity from drug trials

Moonlake's readout produced a cash windfall. Risks remain

STAT Readout Newsletter: Today's biggest biotech updates

BioMarin wins approval for gene therapy to treat hemophilia A

Lawmakers consider Medicare pay reforms for doctors

Alkermes shareholders re

Mike Pence clashes with Tucker Carlson in Iowa

Wildfire smoke exposes gaps in outdoor worker protections

How climate

hotspot

FDA struggles to regulate food additives, sometimes for decades

Eli Lilly expects to double planned employment in Boston center

Congress: Eradicate hepatitis C and reduce the deficit

Congress: Eradicate hepatitis C and reduce the deficit

Researchers explore possible ties between long Covid, menopause

Federal judge rules Oregon’s tough new gun law is constitutional

focus

knowledge

focus

knowledge